Psychcro is part of AWAKN Life Sciences and has jet to independently publish their website/news/etc.
Psychcro
From their investor presentation:
Market conditions
With a growing tide of clinical trials by a small network of Universities globally, there is a need for an independent niche CRO with a focus on psychopharmacology. A multitude of commercial entities are now undertaking research for new medicines and new therapy protocols – this is our market.
Market positioning
Specialised psychoactive treatments for mental health disorders validated under the scientific rigour of PSYCHCRO’s specialist teams. From study design, to participant enrollment, to clinical execution, and regulatory submissions, our senior psychedelic scientists and partners create data-driven IP for our clients to thrive.
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates